Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Metrics to compare | KTTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKTTAPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −4.1x | −0.5x | |
PEG Ratio | −0.01 | 0.01 | 0.00 | |
Price/Book | 0.4x | 2.8x | 2.6x | |
Price / LTM Sales | - | 153.9x | 3.3x | |
Upside (Analyst Target) | - | 172.0% | 43.5% | |
Fair Value Upside | Unlock | −0.7% | 6.9% | Unlock |